No.1 Kexing Pharmaceutical plans to transfer 100% equity of Tong'an Pharmaceutical for 15 million yuan

On June 10th, Sinopharm announced that it plans to transfer 100% equity of its wholly-owned subsidiary Shenzhen Tong'an Pharmaceutical Co., Ltd. to Guangxi Zhuang Autonomous Region Institute of Materia Medica Co., Ltd. for a transfer price of 15 million yuan. According to the announcement, Tong'an Pharmaceutical has not actually conducted business in recent years. Currently, it mainly holds approval numbers for 20 drugs, including 19 traditional Chinese medicine varieties such as Vitamin C Yinqiao tablets. After the transaction is completed, Sinopharm will no longer hold equity in Tong'an Pharmaceutical, and Tong'an Pharmaceutical will no longer be included in the company's consolidated financial statements.

Comment: The sale of equity in Tong'an Pharmaceutical by Kexing Pharmaceutical is beneficial for the company to continue focusing on the biopharmaceutical field, improve core competitiveness, reduce operational risks, and is in line with the company's long-term strategic development plan. After the completion of this transaction, it is expected to increase the total profit and cash flow of Sinopharm in 2025. The final data is subject to audit results and investors need to keep an eye on it.

NO.2 Resignation of President and Vice President of Renfu Pharmaceutical

On June 10th, Renfu Pharmaceutical announced that the company's board of directors received written resignation reports from director Li Jie, director and president Deng Xiafei, and vice president Li Li'e on June 9th. All three resigned due to personal reasons (retirement) and will gradually handle the resignation procedures for their positions in the holding subsidiary. At the same time, the company has appointed former Vice President Du Wentao as the new President. Data shows that Du Wentao has served as the Vice President of the company from October 2003 to present, and as the President and Director of Yichang Renfu Pharmaceutical Co., Ltd. from April 2014 to present.

Comment: Several executives of Renfu Pharmaceutical have resigned due to retirement, which is a normal personnel change. However, the concentrated departure in the short term may raise concerns in the capital market about the stability and strategic execution of the company's management. The newly appointed CEO Du Wentao is a senior member of the company, and his rich resume will help with a smooth transition. However, the capital market still needs to observe whether he can effectively lead the company's sustainable development. Investors should pay attention to the subsequent performance and strategic progress.

NO.3 Lianhuan Pharmaceutical was fined 61.0382 million yuan for monopoly agreement

On June 10th, Lianhuan Pharmaceutical announced that the company had received an "Administrative Penalty Decision" issued by the Tianjin Municipal Market Supervision and Administration Commission, which determined that the company had reached and implemented a monopoly agreement with a competitor to fix the price of dexamethasone sodium phosphate raw materials, in violation of Article 17 (1) of the Anti Monopoly Law. The regulatory authorities ordered the company to cease its illegal activities and imposed a confiscation of illegal gains of 17.8992 million yuan and a fine of approximately 43.139 million yuan, totaling approximately 61.0382 million yuan.

Comment: Lianhuan Pharmaceutical has been ordered to cease its illegal activities and faces a high fine of over 61 million yuan for violating the Anti Monopoly Law. The capital market may be concerned about its operational stability and profitability as a result. The company's stock price may be under pressure in the short term, and investor confidence may be dampened. The long-term impact depends on the effectiveness of the company's rectification and subsequent compliance performance, and investors need to keep an eye on it.

NO.4 * ST Jingfeng's contractual negligence dispute has been filed, involving a total amount of 76.98 million yuan

On June 10th, * ST Jingfeng issued a notice regarding the company's major lawsuit, stating that the company has been filed and accepted by the court for a contractual fault liability dispute with defendants such as Anquan, Xiaokun, and Azhuohui, involving a total amount of 76.98 million yuan. The announcement shows that there is a dispute over the "Capital Increase Agreement" signed between the plaintiff and the defendant in 2017. The plaintiff believes that the defendant has not fulfilled its capital contribution obligations and that the defendant had inflated net profits before the capital increase, resulting in losses to the company. The plaintiff requests the court to order the defendant to jointly compensate for the losses and bear the related litigation costs.

Comment: The case has not yet been heard in court, and the company's party status is the plaintiff. Due to the ongoing litigation, it is currently impossible to predict the impact on the company's current or future profits. However, the capital market may be concerned about the stability and financial condition of the company's operations, the uncertainty of litigation outcomes, or the impact on investor confidence. The short-term volatility risk of stock prices increases, and the long-term impact depends on the progress of litigation and the final ruling.

Announcement on Abnormal Fluctuations in Stock Trading by NO.5 Zhongsheng Pharmaceutical Co., Ltd

On June 10th, Zhongsheng Pharmaceutical announced that the company's stock had experienced abnormal fluctuations in stock trading, with a cumulative deviation of more than 20% from the daily closing price on June 9th and June 10th, 2025, for two consecutive trading days. The company said that the Phase III clinical trial of RAY1225 injection in the treatment of overweight/obese patients and the two Phase III clinical trials for patients with type 2 diabetes had obtained the ethical approval for clinical trials, and the progress of clinical trials was uncertain.

Comment: Recently, several A-share pharmaceutical listed companies have announced abnormal fluctuations in stock trading, but there are doubts about whether the products under research can support high stock prices. For example, although the Phase III clinical trial of Zhongsheng Pharmaceutical's under research product RAY1225 injection for overweight/obesity and type 2 diabetes patients has received ethical approval, the progress is still uncertain. The capital market needs to be alert to the risk of callback after the irrational rise of stock prices, and rationally view the company's future research and development achievements and market prospects.

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. Based on this operation, the risk is borne by oneself.